Xenon Pharmaceuticals Inc Quick Ratio (XENE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Xenon Pharmaceuticals Inc   (NASDAQ: XENE)

Xenon Pharmaceuticals Inc 's Quick Ratio

XENE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 10.85 below Xenon Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Quick Ratio than Xenon Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 126 to 367.

Explain Quick Ratio?
How much Cash & cash equivalents XENE´s has?
What are XENE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XENE Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 159.62 % 24.31 % 119.63 % 29.1 % 5.63 %
Y / Y Cash & cash equivalent Change 90.89 % 99.18 % -12.45 % -29.32 % -32.43 %
Quick Ratio MRQ 10.85 27.5 7.02 12.06 14.75
XENE's Total Ranking # 367 # 126 # 242 # 244 # 140
Seq. Current Liabilities Change 115.48 % -49.06 % 103.91 % 16 % 3.18 %
Seq. Cash & cash equivalent Change -14.99 % 99.45 % 18.74 % -5.18 % -11.3 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 148
Overall Market # 367


Quick Ratio Statistics
High Average Low
67.39 18.7 1.97
(Mar 31 2022)   (Dec 31 2013)




Financial Statements
Xenon Pharmaceuticals Inc 's Current Liabilities $ 86 Millions Visit XENE's Balance sheet
Xenon Pharmaceuticals Inc 's Cash & cash equivalent $ 931 Millions Visit XENE's Balance sheet
Source of XENE's Sales Visit XENE's Sales by Geography


Cumulative Xenon Pharmaceuticals Inc 's Quick Ratio

XENE's Quick Ratio for the trailling 12 Months

XENE Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 85.72 % 47.25 % 52.85 % 25.82 % 23.54 %
Y / Y Cash & cash equivalent TTM Growth 30.99 % 1.62 % -24.19 % -21.63 % -10.36 %
Quick Ratio TTM 12.54 13.7 11.28 15.3 17.78
Total Ranking TTM # 3501 # 3016 # 1895 # 2505 # 2133
Seq. Current Liabilities TTM Growth 27.86 % 4.29 % 30.63 % 6.63 % 1.37 %
Seq. Cash & cash equivalent TTM Growth 17.09 % 26.61 % -3.67 % -8.27 % -9.17 %

Quick ratio ranking by company, industry and sector >> Back to XENE Financial Strength Comparisons >> Go to Compare XENE Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $85.80 millions, cumulative Quick Ratio decreased to 12.54 above the XENE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Xenon Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3016 to 3501.

Explain Quick Ratio?
How much Cash & cash equivalents XENE´s has?
What are XENE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 420
Healthcare Sector # 855
Within the Market # 3501


trailing twelve months Quick Ratio Statistics
High Average Low
16.25 6.72 1.11
(Sep 30 2016)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions

Date modified: 2026-09-26T07:24:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.